25-hydroxyvitamin-d-2 and Coronary-Disease

Deficiency of vitamin D is known to be effective in the development of hypertension, coronary artery disease, myocardial infarction, and stroke. Deficiency of vitamin D was also shown to be associated with new onset atrial fibrillation (AF) by activating the renin-angiotensin system. This study investigated whether or not levels of vitamin D are effective in the development of AF after coronary artery bypass grafting (CABG) surgery.. A total of 283 patients undergoing CABG were included in this study. Clinical information, history of medication use, serum 25 hydroxy(OH) vitamin D, and calcium levels of all patients were evaluated preoperatively.. AF developed postoperatively in 72 (25%) of patients. Serum 25(OH) vitamin D levels of patients in whom AF developed after CABG were significantly lower than patients in whom AF did not occur (15.6 ± 7.4 versus 19.1 ± 9.1; P = .004). Independent variables which were predictors of AF development in multivariate logistic regression analysis were ejection fraction (odds ratio [OR]: 0.93; 95% confidence interval [CI] 0.89-0.97; P = .003), left atrial dimensions (OR: 1.47; 95% CI 1.26-1.71; P < .001), and serum 25(OH) vitamin D levels (OR: 0.95; 95% CI 0.91-0.99; P = .035).. This study has shown that deficiency of vitamin D is associated with new onset AF post-CABG surgery.

Topics: 25-Hydroxyvitamin D 2; Aged; Atrial Fibrillation; Coronary Artery Bypass; Coronary Disease; Electrocardiography; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Risk Factors; Time Factors; Turkey; Vitamin D Deficiency

Several studies suggested that low serum concentrations of 25-hydroxyvitamin D (25(OH)D) are associated with an increased risk of cardiovascular disease (CVD). However, the evidence is still inconclusive, mostly based on CVD mortality and studies with single 25(OH)D measurements.. We aimed to assess the association of 25(OH)D with fatal and nonfatal CVD in the same study population, using repeated 25(OH)D measurements and competing risks analysis.. This was a population-based cohort study (ESTHER study, baseline 2000-2002). Follow-up data, including survival status, were collected after 2, 5, and 8 years. The response rate for survival was 99.9%.. Participants were recruited during a health screening examination by their general practitioners. 25(OH)D was measured in blood samples collected at baseline and the 5-year follow-up visit.. A total of 9949 men and women, aged 50 to 74 years at baseline, with sufficient knowledge of the German language and resident in the German state of Saarland were included in the study.. Outcomes included CVD, coronary heart disease (CHD), and stroke, in total and differentiated into fatal and nonfatal events.. Overall, 854 study participants had a nonfatal and 176 a fatal CVD event during 8 years of follow-up. Comparing subjects with 25(OH)D levels below 30 nmol/L and above 50 nmol/L resulted in a hazard ratio of 1.27 (95% confidence interval = 1.05-1.54) for total CVD and 1.62 (95% confidence interval = 1.07-2.48) for fatal CVD in a model adjusted for important potential confounders. No significant association for nonfatal CVD was observed. In dose-response analysis, we observed an increased cardiovascular risk at 25(OH)D levels below 75 nmol/L. Results for CHD and stroke were comparable to the results obtained for the composite outcome CVD.. Our results support evidence that low 25(OH)D levels are associated with moderately increased risk of CVD and indicate that the observed association is much stronger for fatal than for nonfatal events.

Topics: 25-Hydroxyvitamin D 2; Aged; Calcifediol; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Female; Follow-Up Studies; Germany; Humans; Incidence; Male; Middle Aged; Models, Biological; Risk Assessment; Risk Factors; Severity of Illness Index; Stroke; Survival Analysis; Vitamin D Deficiency